Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (March 2020)

27 slides from Aerie Pharmaceuticals's investor presentation, Mar 31, 2020

  1. Slide 1: Company Overview Investor Presentation March 2020

    Company Overview Investor Presentation March 2020 Exhibit 99.1

  2. Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Aerie Overview Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indicat

  4. Slide 4: Aerie Overview: 2019 U.S. Glaucoma Market

    Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Estimated Glaucoma Market TRx Mix - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3

  5. Slide 5: Rocklatan Phase 3 Month 12 Responder Analysis

    For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

  6. Slide 6: Topline Results from Rhopressa Phase 4 MOST Study

    Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

  7. Slide 7: U.S. Glaucoma Franchise Launch Update

    For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 3/27/2020 IQVIA Weekl

  8. Slide 8: U.S. Glaucoma Franchise: TRx/NRx % Change versus prior week

    U.S. Glaucoma Franchise: TRx/NRx % Change versus prior week For Investor Use Source: IQVIA Rhopressa® bottles per Rx for year-to-date week ending 3/20/2020 were 1.37 compared to March Quarter 2019 of 1.27, reflecting an increase in 90 days’ supply. TRx % Change Versus Prior Week NRx % Change Versus

  9. Slide 9: TRx Growth By Branded Product

    TRx Growth By Branded Product For Investor Use Product Dec ‘19 TRx Change from Dec ‘18 Aerie Franchise 45,798 24,506 Vyzulta® 13,796 5,752 Combigan® 159,299 2,877 Zioptan® 12,298 130 Lumigan® 201,668 137 Simbrinza® 42,666 (826) Cosopt PF® 5,268 (3,875) Alphagan® P 82,949 (4,365) Azopt® 43,486 (9,362

  10. Slide 10: Aerie & COVID-19: U.S. Sales Activities

    Aerie & COVID-19: U.S. Sales Activities Sales: Virtual contact and email blasts Sales reps interactively communicating with physicians via Zoom Two email blasts per week to 9,000 physicians, covering MOST data and other product background Webinars for physicians (replacing local speaker meetings) On

  11. Slide 11: Aerie & COVID-19: Ex-U.S. Activities & Pipeline

    Aerie & COVID-19: Ex-U.S. Activities & Pipeline Ex-U.S. Activities Europe: Mercury 3 readout potentially by late 2020 Japan: PMDA meeting scheduled for Q2 2020 Pipeline AR-1105: Enrollment complete; readout for H2 20 remains on track AR-13503: Minimum enrollment complete, study remains on track to b

  12. Slide 12: Market Access as of March 2020

    For Investor Use Market Access as of March 2020 Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Commercial ~ 90% of covered lives Medicare Part D ~ 75% of covered lives Rocklatan® Commercial ~ 88% of covered lives Medicare Part D ~ 3

  13. Slide 13: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i

  14. Slide 14: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful top-line results released in November 2019 Phase 3 trials expected to be conducted in Japan Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2019. *TRx calculated from IQVIA unit data (1 month = 1 TRx) Aer

  15. Slide 15: AR-13324-CS208 Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  16. Slide 16: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

  17. Slide 17: U.S. Dry Eye Market

    For Investor Use U.S. Dry Eye Market Estimated 30 million dry eye sufferers in the United States Less than 3 million treated Sources: Mixture of public information, IQVIA , Market Scope and estimates – Feb 2020 US 2019 Sales: $1.6B est.

  18. Slide 18: AVX-012 (now named AR-15512) for Dry Eye

    For Investor Use AVX-012 (now named AR-15512) for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors TRPM8 receptor is a cold thermoreceptor involved in basal tear production (i.e.; sign) Modulation of TRPM8 also provides a cooling sensation upon instillation (i.e.; symptom) T

  19. Slide 19: AR-15512 (TRPM8 Agonist) for Dry Eye: How AR-15512 works

    AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

  20. Slide 20: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights

    AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Symptoms: SANDE Score Percentage of patients improving ≥20 score

  21. Slide 21: Bringing Small Molecule Therapy to Back of the Eye

    Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small molecules address a wider array of therapeutic

  22. Slide 22: Aerie's Ophthalmic Implant Platform

    For Investor Use Aerie’s Ophthalmic Implant Platform Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug candi

  23. Slide 23: 2019 U.S. Retinal Disease Market

    For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

  24. Slide 24: Aerie's Sustained Implant Opportunities

    For Investor Use Aerie’s Sustained Implant Opportunities Markets in Need of Further Innovation: Retinal Vein Occlusion (RVO) Wet Age Related Macular Edema (wAMD) Diabetic Macular Edema (DME) Broadly Underserved Market Opportunities: Glaucoma Neuro-enhancement Dry AMD/Geographic Atrophy (GA)

  25. Slide 25: Aerie's Lead Implant Product Candidates

    For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout ~ H2 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administr

  26. Slide 26: Aerie's Key Catalysts for 2020

    Aerie’s Key Catalysts for 2020 Pipeline: Avizorex TRPM8 agonist for Dry Eye Phase 2/3 clinical study expected to commence H2 2020 AR-1105 Phase 2 RVO clinical study readout expected H2 2020 AR-13503 stage 2 clinical study expected to commence H2 2020 Globalization: Roclanda® Mercury 3 topline readou

  27. Slide 27: Summary: Key Priorities

    For Investor Use Summary Key Priorities Successful commercialization in U.S. of Rhopressa® and Rocklatan® Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Avizorex TRPM8 agonist for dry eye Retina Program Well-Financ

Aerie Pharmaceuticals — Investor Presentation (March 2020) on 6ix